Zealand Pharma's Weight-Loss Drug Petrelintide Shows Promising Trial Results, Shares Surge 17%
TL;DR Summary
Zealand Pharma's shares surged 18% after positive early-stage trial results for its weight loss drug petrelintide, which showed an average body weight reduction of 8.6% compared to 1.7% with a placebo. The drug was deemed safe and well-tolerated, positioning it as a potential alternative to GLP-1 receptor agonist-based therapies like Novo Nordisk's Ozempic. The company plans to proceed with a phase 2 clinical trial.
Topics:business#businesshealth#clinical-trial#petrelintide#stock-market#weight-loss-drug#zealand-pharma
- Weight loss drug contender Zealand Pharma jumps 17% on trial results CNBC
- Zealand Pharma posts positive trial results for its Ozempic alternative petrelintide Quartz
- Zealand Pharma shares surge after positive results of weight-loss drug that could contend with GLP-1s MarketWatch
- Zealand's amylin-targeting drug shows early potential in obesity STAT
- Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide Yahoo Finance
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 2 min read
Condensed
83%
384 → 64 words
Want the full story? Read the original article
Read on CNBC